Neuroleptic malignant syndrome and the acute phase response

Journal of Clinical Psychopharmacology

Volumn 28, Issue 4, 2008, Pages 459-461

  Rosebush, Patricia I ^a   Anglin, Rebecca E ^a   Richards, Carl ^b   Mazurek, Michael F ^a  

^a Department of Psychiatry and Behavioural Neurosciences ^*

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA 1 ANTICHYMOTRYPSIN; C REACTIVE PROTEIN; CREATINE KINASE; FIBRINOGEN; INTERLEUKIN 6; IRON; LORAZEPAM; PARACETAMOL; PROSTAGLANDIN INHIBITOR; SALICYLIC ACID; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE; ACUTE PHASE PROTEIN; BENZODIAZEPINE RECEPTOR AFFECTING AGENT;

ACUTE PHASE RESPONSE; ADOLESCENT; CASE REPORT; CATATONIA; ERYTHROCYTE SEDIMENTATION RATE; HEAT STRESS; HUMAN; LETTER; MALE; MENTAL STRESS; MUSCLE INJURY; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ACUTE-PHASE PROTEINS; ACUTE-PHASE REACTION; ADOLESCENT; GABA MODULATORS; HUMANS; LORAZEPAM; MALE; NEUROLEPTIC MALIGNANT SYNDROME;

EID: 54449084691     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31817ea9c1     Document Type: Letter

References (15)

1. Rosebush PI, Stewart T. A prospective analysis of24 episodes ofneuroleptic malignantsyndrome. Am JPsychiatry. 1989;146:717-725.
2. Rosebush PI, Mazurek M. Serum iron and neuroleptic malignant syndrome. Lancet. 1991;338:149-151.
3. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
4. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome: are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry. 1991;159:709-712.
5. Konzman JP, Parnet P, Dantzer R. Cytokine- induced sickness behaviour: mechanisms and implications. TINS. 2002;25:154-159.
6. Taylor C, Rogers G, Goodman C, et al. Hematologic, iron-related and acute-phase protein responses to sustained strenuous exercise. JAppl Physiol. 1987;62:464-469.
7. Black PH. The inflammatory response is an integral part of the stress response: implications for atherosclerosis, insulin resistance, type 11 diabetes and metabolic syndrome X. Brain Behav Immun. 2003;17:350-364.
8. Deak T, Meriwether JL, Fleshner M, et al. Evidence that brief stress may induce the acute phase response in rats. Am J Physiol. 1997; 273:1998-2004.
9. Lee JWY. Serum iron in catatonia and neuro- leptic malignant syndrome. Biol Psychiatry. 1998;44:499-507.
10. White DAC. Catatonia and the neuroleptic malignantsyndrome- asingleentity?Br JPsychiatry. 1992;161:558-560.
11. Rosebush PI, Hildebrand A, Furlong B, et al. Catatonic syndrome on a general psychiatric ward: frequency, clinical presentation and response to lorazepam. J Clin Psychiatry. 1990; 51:357-362.
12. Naganuma H, Fugii I. Incidence and risk factors in neuroleptic malignantsyndrome. Acta Psychiatr Scand. 1994;90:424-426.
13. Bouchama A, Knochel JP. Heat stroke. NEngl J Med. 2002;346:1978-1988.
14. Hermesh H, Shiloh R, Epstein Y, et al. Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. Am J Psychiatry. 2000;157:1327-1329.
15. Baracos V, Rodemann HP, Dinarello CA, et al. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin 1). N Engl J Med. 1983;308:553-555.